Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial

Background: COVID-19 is an asymptomatic condition in 40% of cases, and most symptomatic patients present with mild/moderate disease not requiring hospitalization or intensive care, especially during the Omicron wave, when the hospitalization rate was estimated to be 0.3%. The main port of entry for...

Descripción completa

Detalles Bibliográficos
Autores principales: Cegolon, Luca, Mastrangelo, Giuseppe, Emanuelli, Enzo, Camerotto, Riccardo, Spinato, Giacomo, Frezza, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696981/
https://www.ncbi.nlm.nih.gov/pubmed/36432693
http://dx.doi.org/10.3390/pharmaceutics14112502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696981/
https://www.ncbi.nlm.nih.gov/pubmed/36432693
http://dx.doi.org/10.3390/pharmaceutics14112502

Ejemplares similares